( MENAFN - ACCESSWIRE) LUND, SE / ACCESSWIRE / June 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; nasdaq Stockholm:CANTA), today announced the strengthening of its management team through the recruitment of Ton Berkien as Chief Business Officer. At Cantargia, he will be responsible for business development efforts and continue to maintain and foster relationships with leading Pharmaceutical and biotechnology companies. Ton has a solid background through approximately 30 years in pharma, biotech, investment and consulting with significant experience in business development.
He will commence his role October 1, 2024 " I am extremely pleased that Ton has decided to join Cantargia to take responsibility of and strengthen our business development activities. Cantargia has made significant progress in the nadunolimab and CAN10 clinical programs, both forming the base for next steps in our business development activities, " said Göran Forsberg, CEO of Cantargia. Ton Berkien previously held senior business development positions at Amgen, Nuevolution, Takeda and Nycomed.
Before that he held positions at Ferring, PWC, Rijnconsult, KPMG and Gilde Investment Management. He joins from the position as Chief Business Officer at Ultimovacs. Ton Berkien has a BA degree in economics from Saxion University of Applied Sciences in the Netherlands, as well as an LSid from PwC/Harvard Business School/IMD.
Ton is a Dutch and Swedish citizen and lives in Sweden. " It's with great pleasu.
